Explore the infographic below to see how GLP-1s are transforming what ends up in shoppers cartsand how brands can stay ahead of the shift.
After this period, the dose increases systematically: Weeks 5-8: 0.5 mg weekly Weeks 9-12: 1.0 mg weekly Weeks 13-16: 1.7 mg weekly Week 17 onward: 2.4 mg weekly You need to inject the medication under the skin in your abdomen, thigh, or upper arm
This repositions GLP-1 receptor agonists like semaglutide 2.4 mg as true cardiometabolic therapies rather than just anti-obesity drugs
It is for patients with either: A body mass index (BMI) of 30 kg/m2 or greater A BMI of 27 kg/m2 or greater with at least one weight-related ailment such as type 2 diabetes, hypertension, sleep apnea, or others
doi: 10.1111/ijcp.13731 Summary Keywords body weight, glycated hemoglobin (HbA 1c ), efficacy, glucagon-like peptide-1 receptor agonist (GLP-1RA), oral, semaglutide, subcutaneous, type 2 diabetes Citation Meier JJ (2021) Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation